Fiche publication
Date publication
mai 2010
Journal
Molecular cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CORNILLET-LEFEBVRE Pascale
,
Pr DELMER Alain
Tous les auteurs :
Moussay E, Palissot V, Vallar L, Poirel HA, Wenner T, El Khoury V, Aouali N, Van Moer K, Leners B, Bernardin F, Muller A, Cornillet-Lefebvre P, Delmer A, Duhem C, Ries F, van Dyck E, Berchem G
Lien Pubmed
Résumé
Chronic lymphocytic leukemia (CLL) cells are often affected by genomic aberrations targeting key regulatory genes. Although fludarabine is the standard first line therapy to treat CLL, only few data are available about the resistance of B cells to this purine nucleoside analog in vivo. Here we sought to increase our understanding of fludarabine action and describe the mechanisms leading to resistance in vivo. We performed an analysis of genomic aberrations, gene expression profiles, and microRNAs expression in CLL blood B lymphocytes isolated during the course of patients' treatment with fludarabine.
Mots clés
Aged, Antineoplastic Agents, therapeutic use, Comparative Genomic Hybridization, Drug Resistance, Neoplasm, genetics, Female, Gene Expression, drug effects, Gene Expression Profiling, Genes, myc, genetics, Humans, In Situ Hybridization, Fluorescence, Leukemia, Lymphocytic, Chronic, B-Cell, drug therapy, Male, MicroRNAs, genetics, Middle Aged, Oligonucleotide Array Sequence Analysis, Reverse Transcriptase Polymerase Chain Reaction, Tumor Suppressor Protein p53, genetics, Vidarabine, analogs & derivatives
Référence
Mol. Cancer. 2010 May;9:115
